GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...
GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...
